Camurus achieves ESG risk rating ‘low’ by Sustainalytics

Camurus has been recognized for its strong sustainability performance, receiving ESG risk rating low in the latest assessment by the independent ESG research and rating firm Sustainalytics. This rating reflects a low risk of experiencing material financial impact from environmental, social, and governance (ESG) factors.

“Sustainability is embedded throughout our business, and we have made strong progress in advancing our strategic sustainability work in recent years”, says Fredrik Tiberg, President & CEO of Camurus. “This improved risk rating is a testament to our long-term commitment, strong teamwork, and the value of our core business – improving access to innovative medicines that can bring significant benefits to patients, caregivers, and society.”

As part of the company’s commitment to responsible innovation, Camurus is advancing several key sustainability initiatives, such as certification of all laboratories under the My Green Lab standard*, transitioning to renewable energy sources to reduce the company’s carbon footprint, and completion of a comprehensive greenhouse gas inventory, covering emissions across the entire value chain. Camurus also works closely with vendors and partners to improve performance in areas such as human rights, environmental stewardship, and business ethics.

“We are proud of the progress we are making“, says Iris Rehnström, Director Sustainability at Camurus. “We work strategically to reduce risks throughout our value chain, and the ongoing initiatives reflect our long-term commitment to environmental stewardship and responsible business practices.”

Sustainalytics’ ESG risk rating is based on a comprehensive analysis of environmental, social, and governance factors. This includes areas such as greenhouse gas emissions and energy use, human rights in the value chain, product safety, access to medicine, as well as business ethics and anti-corruption practices.

For Sustainalytics’ results see:  https://www.sustainalytics.com/esg-rating/camurus-ab/1008297536

For information about Camurus’ sustainability work, see: https://www.camurus.com/sustainability/

*Globally recognized gold standard for sustainability in laboratory environments: https://mygreenlab.org/

About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal^® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn.